A robust pipeline of novel, precisely targeted CNS therapies for genetically defined patient populations

ESCAPE Bio is building a diverse pipeline of first- and best-in-class small molecule therapeutics in major areas of unmet need within neurodegeneration.
ESB1609 is a novel, orally administered, brain-penetrant and selective sphingosine-1-phosphate 5 (S1P5) receptor agonist being developed for Niemann-Pick C disease (NPC) and other neurodegenerative diseases caused by CNS sphingolipid dysmetabolism.
ESB5070 is a novel, orally administered, brain-penetrant and highly selective LRRK2 G2019S kinase inhibitor being developed for the treatment of Parkinson’s disease (PD) patients carrying the G2019S LRRK2 variant.
ESCAPE is developing small-molecule allosteric structure modulators that alter ApoE4 protein structure to restore normal ApoE function and will have the potential to treat ApoE4 carriers with Alzheimer’s disease.
ESB1609 (S1P5 SELECTIVE AGONIST), INITIALLY FOR DEVELOPMENT IN NIEMANN-PICK C DISEASE
ESB5070 (LRRK2 KINASE INHIBITOR) FOR PARKINSON’S DISEASE PATIENTS WITH THE G2019S VARIANT
STRUCTURE MODULATOR OF APOE4 FOR ALZHEIMER’S DISEASE